Regeneron (REGN) Q1 2026 Earnings Transcript

Regeneron reported first-quarter revenue of $3.6 billion, up 19%, and non-GAAP EPS of $9.47, up 15%, driven by strong DUPIXENT, EYLEA HD and Libtayo sales. Management also highlighted major pipeline progress, including FDA approval of Otarmeni, priority review for garetosmab, and positive Phase III cemdisiran data, while authorizing a new $3 billion share repurchase program. Offset to the upbeat results was a temporary Limerick manufacturing interruption that cut GAAP gross margin to 76% and led to 2026 margin guidance being lowered to 77%-78%.

Analysis

REGN is increasingly a story of franchise durability plus optionality, not just headline earnings. The market is likely underappreciating that DUPIXENT is becoming a reusable immunology platform with enough adjacent indications and next-gen assets to extend growth well beyond the current patent debate; that lowers terminal multiple risk even if the stock is still trading like a mature biotech. The real second-order effect is on Sanofi: once the development balance clears, REGN’s economics step up without requiring incremental commercial spend, while Sanofi absorbs more of the long-tail “rebate wall” defense and lifecycle complexity.

The biggest near-term overhang remains retinal franchise cannibalization, but the erosion is increasingly self-inflicted conversion rather than outright franchise collapse. That matters because EYLEA HD adoption plus a likely device approval can stabilize the mix, yet the second-half biosimilar wave creates a very visible demand gap that should cap multiple expansion until investors see whether HD can offset legacy erosion faster than expected. Temporary manufacturing noise is also less important than it sounds: the real risk is not lost supply, but the gross-margin reset creating a lower near-term earnings baseline just as the next set of catalysts hits.

The upside case is that REGN has several binary-ish readouts clustered over the next 6-9 months that could re-rate the story from “defensive large-cap biotech” to “multi-franchise pipeline compounder.” The underappreciated feature is capital intensity: they can fund multiple late-stage shots on goal and still buy back stock aggressively, which should compress downside in a selloff. The market is probably discounting the pipeline because management is broad rather than precise in messaging; that is often a tell that the data package is better than the street model, not worse.

Key Decisions for Investors

• Long REGN into the next 1-2 quarters on a pullback; use the current gross-margin and EYLEA headline noise to build a position ahead of the catalyst cluster (prefilled syringe, garetosmab PDUFA, cemdisiran decision). Risk/reward favors ~2:1 upside if one of the late-stage assets starts to look commercially meaningful before biosimilar pressure fully shows up.
• Pair trade: long REGN / short SNY for the next 3-6 months. REGN’s valuation should benefit from full economics stepping up after the Sanofi development balance rolls off, while SNY is more exposed to the market’s eventual realization that DUPIXENT growth is still very durable but increasingly capitalized in expectations.
• Sell downside hedged with puts rather than shorting outright: buy REGN stock and finance with 6-9 month out-of-the-money puts. The setup has positive carry because buybacks and multiple catalysts can support the shares, but the EYLEA biosimilar window makes outright short gamma risky.
• If you want event-driven convexity, consider a call spread on REGN into the August garetosmab decision. The asymmetric payoff is that a clean rare-disease approval would validate the “multiple franchise” thesis, while the loss case is largely limited to premium paid.
• Monitor for weakness in SNY on any headline around DUPIXENT lifecycle/partnering friction; if collaboration economics improve, the long REGN / short SNY pair should outperform because REGN gets the leverage while SNY bears more commercialization burden.